Drug intelligence / Profile preview

Arilvax

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Arilvax is a live attenuated vaccine used for the prevention of yellow fever, a viral hemorrhagic fever caused by the yellow fever virus. It contains the 17D strain of the virus, which is grown in chick embryos. Originally developed by Celltech (formerly Medeva), the vaccine's rights transitioned through several companies, including PowderJect, Evans Vaccines, Chiron Vaccines, and Acambis. It is administered as a single-dose subcutaneous injection and induces long-term protective immunity. While it has been marketed in several European and African countries, Acambis pursued a Biological License Application (BLA) in the United States, completing Phase III clinical trials.

Brand names: Arilvax
Other names: yellow fever vaccine

Beyond the preview

Go deeper on Arilvax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arilvax.

Explore the full profile